Choung, Wonken published the artcileIdentification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR, Synthetic Route of 584-02-1, the main research area is drug discovery antidiabetics PPARgamma agonist SAR type 2 diabetes; Antidiabetics; Drug discovery; PPARgamma agonist.
The new class of PPARgamma non-TZD agonist originally derived from the backbone of anti-hypertensive Fimasartan, BR101549, was identified as a potential lead for anti-diabetic drug development. The X-ray crystallog. of BR101549(I) with PPARgamma ligand binding domain (LBD) revealed unique binding characteristics vs. traditional TZD full agonists. The lead candidate, BR101549, has been found activating PPARgamma to the level of Pioglitazone in vitro and indeed has demonstrated its effects on blood glucose control in mouse proof-of-concept evaluation. The attempts to improve its metabolic stability profile through follow-up SAR including deuterium incorporation have been also described.
Bioorganic & Medicinal Chemistry Letters published new progress about Adiponectins Role: BSU (Biological Study, Unclassified), BIOL (Biological Study). 584-02-1 belongs to class alcohols-buliding-blocks, name is 3-Pentanol, and the molecular formula is C5H12O, Synthetic Route of 584-02-1.
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts